CEA as a prognostic factor in colorectal cancer

Area of Science:

• Oncology
• Gastroenterology
• Clinical Chemistry

Background:

• Colorectal cancer (CRC) is a significant global health concern.
• Carcinogenic embryonic antigen (CEA) is a tumor marker often used in CRC management.
• Understanding CEA's role in different CRC locations is crucial for accurate staging and prognosis.

Purpose of the Study:

• To investigate the sensitivity and prognostic value of serum CEA levels in patients with colorectal cancer.
• To determine if CEA's utility differs based on the primary tumor location (right colon, left colon, or rectum).

Main Methods:

• Serum CEA levels were measured in 207 patients diagnosed with colorectal cancer.
• Statistical analyses were performed to assess CEA sensitivity and prognostic value in relation to tumor location and stage (Dukes stage).

Main Results:

• CEA sensitivity was significantly associated with tumor stage for right-sided colon tumors, but not for left-sided or rectal tumors.
• CEA demonstrated prognostic value for right-sided colon tumors (p < 0.001), but not for left-sided or rectal tumors.
• CEA did not provide prognostic value independent of Dukes stage, even for right-sided colon tumors.

Conclusions:

• Serum CEA levels exhibit differential sensitivity and prognostic significance depending on the primary tumor location within the colorectum.
• The findings highlight the importance of considering tumor location when interpreting CEA levels in colorectal cancer patients.
• CEA's prognostic utility is limited and should be considered alongside other staging information, particularly the Dukes stage.